EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological regulators of Hippo pathway: Advances and challenges of drug development

Zhaobai Lao iD, Xin Chen, Bin Pan iD, Bin Fang, Wanlei Yang, Yu Qian

The FASEB Journal · 31.03.2025 · 39 (6)

DOI: 10.1096/fj.202401895rr ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 18.03.2025. Verfasst von Zhaobai Lao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medi…. Hauptthemen laut MEDLINE: Signal Transduction, Protein Serine-Threonine Kinases, Drug Development. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), MOST | NSFC | NSFC-Zhejiang Joint Fund | | Natural Science Foundation of Zhejiang Province (ZJNSF), National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hippo signaling pathway is crucial in regulating organ size, tumor progression, tissue regeneration, and bone homeostasis. Inactivation of the Hippo pathway results in the nuclear translocation and activation of YAP/TAZ. This activation not only promotes tumor progression but also enhances tissue regeneration, wound healing, and maintenance of bone stability Although its discovery occurred over two decades ago, developing effective inhibitors or activators for the Hippo pathway remains challenging. Recently, however, the pace of advancements in developing Hippo signaling‐related agonists and antagonists has accelerated, with some drugs that target TEAD advancing to clinical trials and showing promise for treating related diseases. This review summarizes the progress in research on Hippo signaling‐related agonists and inhibitors, offering an in‐depth analysis of their regulatory mechanisms, pharmacological properties, and potential in vivo applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionProtein Serine-Threonine KinasesDrug DevelopmentHumansHippo Signaling PathwayAnimalsNeoplasms

Stichwörter der Autor:innen

Hippo pathwayLATS1/2MST1/2TEADsYAP/TAZagonistinhibitor

Substanzen

Protein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Orthopedics Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.

ORCID-Profile: Zhaobai Lao, Bin Pan

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • MOST | NSFC | NSFC-Zhejiang Joint Fund | | Natural Science Foundation of Zhejiang Province (ZJNSF)
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Lao, Z., Chen, X., Pan, B., Fang, B., Yang, W., & Qian, Y. (2025). Pharmacological regulators of Hippo pathway: Advances and challenges of drug development. The FASEB Journal, 39(6). https://doi.org/10.1096/fj.202401895rr

Vancouver

Lao Z, Chen X, Pan B, Fang B, Yang W, Qian Y. Pharmacological regulators of Hippo pathway: Advances and challenges of drug development. The FASEB Journal. 2025;39(6). doi:10.1096/fj.202401895rr

BibTeX
@article{Lao2025,
  author = {Lao, Zhaobai and Chen, Xin and Pan, Bin and Fang, Bin and Yang, Wanlei and Qian, Yu},
  title = {Pharmacological regulators of Hippo pathway: Advances and challenges of drug development},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {6},
  doi = {10.1096/fj.202401895rr}
}
Kostenlos starten →